Global Benign Prostatic Hyperplasia Pipeline Overview of Companies and Drug Profile in H1 2017


Posted June 5, 2017 by justinebiel

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

 
2017 Benign Prostatic Hyperplasia pipeline market report of on global industry analysis and opportunity assessment H1 report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1010746

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

H1 Benign Prostatic Hyperplasia pipeline companies are Addex Therapeutics Ltd, AndroScience Corp, Aphios Corp, BCWorld Pharm Co Ltd, Biolab Farmaceutica Ltda, Chong Kun Dang Pharmaceutical Corp, Curadis GmbH, Dongkook Pharmaceutical Co Ltd, GL Pharm Tech Corp, Hanmi Pharmaceuticals Co Ltd, Health Ever Bio-Tech Co Ltd, Jeil Pharmaceutical Co Ltd, Kaken Pharmaceutical Co Ltd, MEI Pharma Inc, Meiji Seika Pharma Co Ltd, Mezzion Pharma Co Ltd, Monosol Rx LLC, Nymox Pharmaceutical Corp, Ono Pharmaceutical Co Ltd, OPKO Health Inc, SK Chemicals Co Ltd, SOM Biotech SL, Sophiris Bio Inc, Vantia Therapeutics, XuanZhu Pharma Co Ltd, Yungjin Pharm Co Ltd.

Drug Profiles of ADX-68692, ASC-JM.X2, AUS-131, BCWPE-004, BL-214, CR-1447, fadanafil, fedovapagon, fexapotide triflutate, KKM-1202 , L-1AD3, MCS-2, NCE-403, ONO-8430506, S-0131632, S-40542, SOM-2391, SOM-2393, tadalafil, talaporfin sodium, tamsulosin hydrochloride CR, tamsulosin hydrochloride DR, tertomotide, topsalysin, TT-701, udenafil, YOB-1604.

Purchase this research report Direct from http://www.reportsnreports.com/purchase.aspx?name=1020029

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
- The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

Inquire more on this Research Report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1020029

List of Figures
Number of Products under Development for Benign Prostatic Hyperplasia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

About Us:
ReportsnReports.com is single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help in purchase decision by mapping your information needs with our huge collection of reports.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By justinebiel
Country India
Categories Health , Industry , News
Tags benign prostatic hyperplasia , benign prostatic hyperplasia market , benign prostatic hyperplasia pipeline , benign prostatic hyperplasia report
Last Updated June 5, 2017